{"id":65770,"date":"2026-05-20T12:20:40","date_gmt":"2026-05-20T04:20:40","guid":{"rendered":"https:\/\/flcube.com\/?p=65770"},"modified":"2026-05-20T12:20:41","modified_gmt":"2026-05-20T04:20:41","slug":"united-laboratories-secures-nmpa-tacit-approval-for-tul108-clinical-study-in-china-following-us-trial-authorization","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65770","title":{"rendered":"United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization"},"content":{"rendered":"\n<p><strong>United Laboratories International Holdings Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3933:HKG\">HKG: 3933<\/a>) announced today it has received <strong>tacit approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to conduct clinical studies for its <strong>Category 1 drug candidate TUL108<\/strong>, a <strong>novel ultra-broad-spectrum \u03b2-lactamase inhibitor<\/strong>. The compound was previously authorized for clinical trials in the United States in January 2026.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Tacit approval, Category 1 innovative drug<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>TUL108 (ultra-broad-spectrum \u03b2-lactamase inhibitor)<\/td><\/tr><tr><td><strong>Previous Approval<\/strong><\/td><td>US FDA clinical trial authorization (January 2026)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>United Laboratories International Holdings Ltd (HKG: 3933)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Novel ultra-broad-spectrum \u03b2-lactamase inhibitor<\/li>\n\n\n\n<li><strong>Target Pathogens:<\/strong> Gram-negative and Gram-positive bacteria, including multidrug-resistant strains<\/li>\n\n\n\n<li><strong>Key Indications:<\/strong> Complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), pulmonary infections, and bloodstream infections<\/li>\n\n\n\n<li><strong>Combination Therapy:<\/strong> Demonstrates enhanced efficacy when combined with meropenem<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Achieves full coverage against clinically challenging carbapenem-resistant Gram-negative bacteria<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-antimicrobial-activity-profile\">Antimicrobial Activity Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Pathogen<\/th><th>Resistance Profile<\/th><th>Sensitivity with TUL108 + Meropenem<\/th><\/tr><\/thead><tbody><tr><td><strong>Escherichia coli<\/strong><\/td><td>Carbapenem-resistant<\/td><td>High sensitivity<\/td><\/tr><tr><td><strong>Klebsiella pneumoniae<\/strong><\/td><td>Carbapenem-resistant<\/td><td>High sensitivity<\/td><\/tr><tr><td><strong>Pseudomonas aeruginosa<\/strong><\/td><td>Carbapenem-resistant<\/td><td>High sensitivity<\/td><\/tr><tr><td><strong>Acinetobacter baumannii<\/strong><\/td><td>Carbapenem-resistant<\/td><td>High sensitivity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The combination of TUL108 with meropenem demonstrates comprehensive activity against the most problematic carbapenem-resistant Gram-negative pathogens, addressing a critical unmet need in the antimicrobial resistance crisis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-outlook\">Market Context &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antimicrobial Resistance Crisis:<\/strong> WHO identifies antimicrobial resistance as one of the top 10 global public health threats, with limited treatment options for carbapenem-resistant infections<\/li>\n\n\n\n<li><strong>Commercial Opportunity:<\/strong> The global anti-infective market for resistant Gram-negative pathogens is projected to exceed $5 billion by 2028<\/li>\n\n\n\n<li><strong>Dual-Market Strategy:<\/strong> United Laboratories&#8217; simultaneous development in both US and China positions the company to address the largest markets for novel antibiotics<\/li>\n\n\n\n<li><strong>Regulatory Incentives:<\/strong> Both US and Chinese regulatory frameworks offer expedited pathways and market exclusivity for novel antibiotics addressing priority pathogens<\/li>\n\n\n\n<li><strong>Healthcare Impact:<\/strong> Successful development could significantly reduce mortality rates associated with carbapenem-resistant infections, which currently exceed 40% in some settings<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and potential therapeutic benefits of TUL108. Actual results may differ materially due to risks inherent in clinical drug development, including safety findings, efficacy outcomes, and regulatory decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051901070_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026051901070_c.\"><\/object><a id=\"wp-block-file--media-a2cbc5c7-5eec-4975-a8d4-34aff3f1b4b8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051901070_c.pdf\">2026051901070_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026051901070_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-a2cbc5c7-5eec-4975-a8d4-34aff3f1b4b8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>United Laboratories International Holdings Ltd (HKG: 3933) announced today it has received tacit approval from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,1260,790],"class_list":["post-65770","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-3933","tag-united-laboratories"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"United Laboratories International Holdings Ltd (HKG: 3933) announced today it has received tacit approval from China&#039;s National Medical Products Administration (NMPA) to conduct clinical studies for its Category 1 drug candidate TUL108, a novel ultra-broad-spectrum \u03b2-lactamase inhibitor. The compound was previously authorized for clinical trials in the United States in January 2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65770\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization\" \/>\n<meta property=\"og:description\" content=\"United Laboratories International Holdings Ltd (HKG: 3933) announced today it has received tacit approval from China&#039;s National Medical Products Administration (NMPA) to conduct clinical studies for its Category 1 drug candidate TUL108, a novel ultra-broad-spectrum \u03b2-lactamase inhibitor. The compound was previously authorized for clinical trials in the United States in January 2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65770\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T04:20:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-20T04:20:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65770#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65770\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization\",\"datePublished\":\"2026-05-20T04:20:40+00:00\",\"dateModified\":\"2026-05-20T04:20:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65770\"},\"wordCount\":363,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 3933\",\"United Laboratories\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65770#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65770\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65770\",\"name\":\"United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-20T04:20:40+00:00\",\"dateModified\":\"2026-05-20T04:20:41+00:00\",\"description\":\"United Laboratories International Holdings Ltd (HKG: 3933) announced today it has received tacit approval from China's National Medical Products Administration (NMPA) to conduct clinical studies for its Category 1 drug candidate TUL108, a novel ultra-broad-spectrum \u03b2-lactamase inhibitor. The compound was previously authorized for clinical trials in the United States in January 2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65770#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65770\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65770#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization - Insight, China&#039;s Pharmaceutical Industry","description":"United Laboratories International Holdings Ltd (HKG: 3933) announced today it has received tacit approval from China's National Medical Products Administration (NMPA) to conduct clinical studies for its Category 1 drug candidate TUL108, a novel ultra-broad-spectrum \u03b2-lactamase inhibitor. The compound was previously authorized for clinical trials in the United States in January 2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65770","og_locale":"en_US","og_type":"article","og_title":"United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization","og_description":"United Laboratories International Holdings Ltd (HKG: 3933) announced today it has received tacit approval from China's National Medical Products Administration (NMPA) to conduct clinical studies for its Category 1 drug candidate TUL108, a novel ultra-broad-spectrum \u03b2-lactamase inhibitor. The compound was previously authorized for clinical trials in the United States in January 2026.","og_url":"https:\/\/flcube.com\/?p=65770","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-20T04:20:40+00:00","article_modified_time":"2026-05-20T04:20:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65770#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65770"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization","datePublished":"2026-05-20T04:20:40+00:00","dateModified":"2026-05-20T04:20:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65770"},"wordCount":363,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 3933","United Laboratories"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65770#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65770","url":"https:\/\/flcube.com\/?p=65770","name":"United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-20T04:20:40+00:00","dateModified":"2026-05-20T04:20:41+00:00","description":"United Laboratories International Holdings Ltd (HKG: 3933) announced today it has received tacit approval from China's National Medical Products Administration (NMPA) to conduct clinical studies for its Category 1 drug candidate TUL108, a novel ultra-broad-spectrum \u03b2-lactamase inhibitor. The compound was previously authorized for clinical trials in the United States in January 2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65770#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65770"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65770#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65770"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65770\/revisions"}],"predecessor-version":[{"id":65772,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65770\/revisions\/65772"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}